Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 3/20 | 0.36 |
| ▸ | STS | P08842 | 1/20 | 0.36 |
| ▸ | CTSS | P25774 | 2/20 | 0.35 |
| ▸ | CTSK | P43235 | 2/20 | 0.35 |
| ▸ | RORC | P51449 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | CTSB | P07858 | 1/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.34 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.34 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3955650 | 1.00 | CTSL (0.36) | CTSLSTSCTSSCTSKRORC | |
| SCHEMBL4212772 | 0.86 | CTSS (0.35) | CTSLCTSSCTSKMAPK1CTSB | |
| SCHEMBL5971691 | 0.82 | MAPK1 (0.36) | CTSLCTSSCTSKMAPK1CTSB | |
| SCHEMBL4768823 | 0.81 | TAS1R3 (0.45) | CTSLCTSSCTSKCTSB | |
| SCHEMBL4768817 | 0.81 | TAS1R3 (0.45) | CTSLCTSSCTSKCTSB | |
| SCHEMBL6605965 | 0.81 | SLC6A2 (0.37) | STSRORCSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6605969 | 0.81 | SLC6A2 (0.37) | STSRORCSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3955656 | 0.81 | STS (0.35) | STSRORCSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6896141 | 0.79 | MAPK1 (0.32) | CTSLCTSSCTSKMAPK1CTSB | |
| SCHEMBL4315427 | 0.78 | MAPK1 (0.40) | CTSLCTSSCTSKMAPK1CTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1796677-A4 | METHOD FOR ACTIVATING TRPV4 CHANNEL RECEPTORS BY AGONISTS | SMITHKLINE BEECHAM CORP (US) | 2009-07-08 | — | — | EP | disclosed |
| EP-1320370-A4 | METHOD OF TREATMENT | SMITHKLINE BEECHAM CORP (US) | 2008-10-22 | — | — | EP | disclosed |
| EP-1796677-A2 | METHOD FOR ACTIVATING TRPV4 CHANNEL RECEPTORS BY AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-06-20 | — | — | EP | disclosed |
| WO-2006029209-A2 | METHOD FOR ACTIVATING TRPV4 CHANNEL RECEPTORS BY AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-03-16 | — | — | WO | disclosed |
| EP-1320370-A1 | METHOD OF TREATMENT | SmithKline Beecham Corporation (US) | 2003-06-25 | — | — | EP | disclosed |
| WO-2002017924-A1 | METHOD OF TREATMENT | SMITHKLINE BEECHAM CORPORATION (GB) | 2002-03-07 | — | — | WO | disclosed |